NCT05862194

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Retrospective, External Comparator Study to Assess the Real-World Effectiveness of Lazertinib as the Second-Line Treatment Versus Platinum-based Chemotherapy in Patients With EGFR Mutation+ Locally Advanced or Metastatic NSCLC

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 534 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This retrospective, external comparator study for Lazertinib aims to assess the real-world effectiveness of Lazertinib as the second-line treatment versus platinum-based chemotherapy in patients with epidermal growth receptor sensitizing mutation-positive, locally advanced or metastatic Non-small Lung cancer.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Lazertinib	Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
DRUG	Platinum-based Chemotherapy	Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period

Timeline

• Start date: 2015-06-01
• Primary completion: 2022-04-30
• Completion: 2023-03-20
• First posted: 2023-05-17
• Last updated: 2023-08-22

Regulatory

• FDA-regulated drug study